Last reviewed · How we verify
glucose solution and Insulin
glucose solution and Insulin is a Small molecule drug developed by HaEmek Medical Center, Israel. It is currently in Phase 1 development. Also known as: Group 1.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | glucose solution and Insulin |
|---|---|
| Also known as | Group 1 |
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- Role of Insulin Action in Psoriasis Pathogenesis
- Relative Contribution of Brain Insulin Action for Postprandial Metabolism (NA)
- Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes (PHASE1, PHASE2)
- Effect of Insulin Lowering on Lipogenesis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glucose solution and Insulin CI brief — competitive landscape report
- glucose solution and Insulin updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI
Frequently asked questions about glucose solution and Insulin
What is glucose solution and Insulin?
Who makes glucose solution and Insulin?
Is glucose solution and Insulin also known as anything else?
What development phase is glucose solution and Insulin in?
Related
- Manufacturer: HaEmek Medical Center, Israel — full pipeline
- Also known as: Group 1
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing